| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 0 | 520 | 13,150 | 12,700 | 7,700 |
| Sales Growth | unch | -96.05% | +3.54% | +64.94% | +563.79% |
| Net Income | 0 | -19,280 | -6,780 | -8,030 | 16,660 |
| Net Income Growth | unch | -184.37% | +15.57% | -148.20% | +176.77% |
Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.